GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL: a randomised controlled trial

Trial Profile

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL: a randomised controlled trial

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms GALACTIC version 1.0
  • Most Recent Events

    • 26 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Mar 2016 Accrual to date is 6% as reported by United kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 4% as reported by United kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top